GP73、AFP异质体联合检测在原发性肝癌早期诊断中的应用进展  

Application progress of joint detection of GP73,AFP corpora heterogeni-um in early diagnosis of primary liver cancer

作　　者：周亮[1] 王世明[1] 

机构地区：[1]山西医科大学第一临床医学院普外科,太原030001

出　　处：《中国当代医药》2015年第4期15-17,共3页China Modern Medicine

摘　　要：原发性肝癌已成为五大恶性肿瘤之一,是导致肿瘤患者死亡的第三大因素。在我国,原发性肝癌更是极为常见的恶性肿瘤之一,死亡率较高,仅次于胃癌、食管癌。一直以来,原发性肝癌诊断是临床上的重点、难点,最近几年,临床上对原发性肝癌的研究取得了显著的进步,治疗方法已从单一外科治疗发展到外科治疗为主、局部治疗为辅、多学科的综合治疗,因此早期发现原发性肝癌对提高临床治疗有效率具有极其重要的作用,尤其是新技术、新方法的出现,明显改善了原发性肝癌的临床诊断和治疗效果,极大地提高了我国原发性肝癌患者的生存率及生活质量。Primary liver cancer（PHC） has become one of the five malignant tumors,is the third major factor leading to the death of patients with cancer.In China,PHC is one of the extremely common malignant tumors with a higher mortality rate,and the mortality rate is next only to gastric cancer,esophageal cancer.All the time since,the diagnosis of PHC is the focus and difficulty in clinical medicine,in recent years,the clinical research on PHC has made significant progress,the treatment method has been developed from the single surgical treatment to the multi-disciplinary comprehensive treatment of surgical treatment mainly,local treatment auxiliarily,therefore early detection of PHC has extremely important role for improving the effective rate of clinical treatment,especially the emergence of new technologies and new methods significantly improve the clinical diagnosis and treatment of PHC,which greatly improve the survival rate and quality of life in patients with PHC in China.

关 键 词：原发性肝癌 早期诊断 GP73 AFP异质体 发展历程 

分 类 号：R735.7[医药卫生—肿瘤]